Tumor progression locus 2 (TPL2): A Cot-plicated progression from inflammation to chronic liver disease

Alejandro H Gutierrez; Marina S Mazariegos; Susana Alemany; Yulia A Nevzorova; Francisco Javier Cubero; Carlos Sanz-García

doi:10.1016/j.bbadis.2023.166660

Tumor progression locus 2 (TPL2): A Cot-plicated progression from inflammation to chronic liver disease

Biochim Biophys Acta Mol Basis Dis. 2023 Apr;1869(4):166660. doi: 10.1016/j.bbadis.2023.166660. Epub 2023 Feb 8.

Authors

Alejandro H Gutierrez¹, Marina S Mazariegos¹, Susana Alemany², Yulia A Nevzorova³, Francisco Javier Cubero³, Carlos Sanz-García⁴

Affiliations

¹ Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, 28040 Madrid, Spain.
² Department of Metabolism and Cell Signaling, Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, 28049 Madrid, Spain; Biomedicine Unit (Unidad Asociada al CSIC), Universidad de Las Palmas de Gran Canaria, 35001 Las Palmas, Spain.
³ Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, 28040 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28029 Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28007 Madrid, Spain.
⁴ Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, 28040 Madrid, Spain. Electronic address: csanz17@ucm.es.

PMID: 36764206
DOI: 10.1016/j.bbadis.2023.166660

Abstract

The cytoplasmic protein tumor progression locus 2 (TPL2), also known as cancer Osaka thyroid (Cot), or MAP3K8, is thought to have a significant role in a variety of cancers and illnesses and it is a key component in the activation pathway for the expression of inflammatory mediators. Despite the tight connection between inflammation and TPL2, its function has not been extensively studied in chronic liver disease (CLD), a major cause of morbidity and mortality worldwide. Here, we analyze more in detail the significance of TPL2 in CLD to shed light on the pathological and molecular transduction pattern of TPL2 during the progression of CLD. This might result in important advancements and enable progress in the diagnosis and treatment of CLD.

Keywords: Cancer Osaka thyroid; Chronic liver disease; Inflammation; MAPK; Tumor progression locus 2; cancer.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Inflammation
Liver Diseases*
MAP Kinase Kinase Kinases
Thyroid Neoplasms*

Substances

MAP Kinase Kinase Kinases
MAP3K8 protein, human